Recent Quotes (30 days)

You have no recent quotes
chg | %

Helix Biopharma Corp.  

(Public, TSE:HBP)   Watch this stock  
Find more results for HBP
0.00 (0.00%)
Delayed:   2:12PM EST
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 1.30 - 2.35
Open     -
Vol / Avg. 0.00/19,761.00
Mkt cap 174.39M
P/E     -
Div/yield     -
EPS -0.11
Shares 84.65M
Beta 0.17
Inst. own 0%
Oct 29, 2015
Full Year 2015 Helix Biopharma Corp Earnings Release

Key stats and ratios

Q3 (Jul '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -95.54% -112.21%
Return on average equity -108.28% -128.76%
Employees 13 -
CDP Score - -


3-305 Industrial Pky S
+1-905-8412300 (Phone)
+1-905-8412244 (Fax)

Website links


Helix BioPharma Corporation is a Canada-based biopharmaceutical company focused on cancer therapy. It is developing products for the treatment and prevention of cancer based on its technologies. The Company’s product development initiatives have focused on its L-DOS47 and Topical Interferon Alpha-2b new drug candidates. It operates through the biopharmaceuticals segment. The Company’s most advanced product clinically is its Topical Interferon Alpha-2b as a treatment for certain skin/mucosal lesions caused by HPV infections. Its DOS47 is a patented oncology platform technology that offers a new and potentially revolutionary approach to the debilitation and destruction of cancer cells. Its L-DOS47 is a new drug in development that offers an approach to the debilitation and destruction of non-small cell lung cancer cells.

Officers and directors

Yvon Bastien Independent Chairman of the Board
Age: 67
Gary Littlejohn Interim Chief Executive Officer, Director
Photios Michalargias Chief Financial Officer
Age: 50
Heman Chao Ph.D. Chief Scientific Officer
Age: 51
Sylwester Cacek Director
Slawomir Majewski M.D. Independent Director
Age: 57
Marek Orlowski Independent Director
Age: 45
Sven Rohmann Independent Director
Age: 51